Graypoint LLC Takes Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Graypoint LLC bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,879 shares of the medical equipment provider’s stock, valued at approximately $472,000.

Several other large investors have also recently made changes to their positions in ZBH. Clear Street Markets LLC purchased a new stake in Zimmer Biomet in the 4th quarter worth about $27,000. Lazard Asset Management LLC increased its holdings in Zimmer Biomet by 70.5% in the 3rd quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 117 shares during the last quarter. Dark Forest Capital Management LP purchased a new position in Zimmer Biomet during the 1st quarter valued at about $35,000. Activest Wealth Management grew its holdings in Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 275 shares in the last quarter. Finally, Peoples Bank KS purchased a new position in Zimmer Biomet during the 3rd quarter valued at about $48,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $124.48 on Monday. The business has a 50 day moving average of $126.73 and a 200 day moving average of $118.94. The company has a market capitalization of $25.58 billion, a price-to-earnings ratio of 25.46, a PEG ratio of 2.29 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $149.25. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. Zimmer Biomet’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.88 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a $0.24 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.77%. Zimmer Biomet’s payout ratio is currently 19.63%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares in the company, valued at $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.70% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. lifted their target price on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, February 9th. Citigroup lifted their target price on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 9th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 target price on shares of Zimmer Biomet in a report on Friday, February 23rd. Finally, Barclays lifted their price target on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research report on Monday, February 12th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $139.39.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.